



09-12-07

1623  
AD

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Zeldis <i>et al.</i>	Confirmation No.:	7262
Serial No.:	09/853,617	Art Unit:	1623
Filed:	May 14, 2001	Examiner:	Patrick T. Lewis
For:	COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER	Attorney Docket No:	9516-022-999
		Docket No:	501872-999021

**SUBMISSION OF REFERENCES**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Further to their response to the Office Action filed October 7, 2007, Applicants note that the references cited in the response may not have been submitted. Therefore, Applicants submit the references for entry into the records and consideration by the Examiner.

Accordingly, enclosed herewith are copies of:


1) *Yamanouchi Pharmaceutical Co., Ltd. v Danbury Pharmacal, Inc.* 231 F.3d 1339, 180 A.L.R. Fed. 743, 56 U.S.P.Q.2d 1641 (2000);

2) Norra MacReady, *Thalidomide Shows Promise in Ovarian Cancer Treatment: Presented at SGO.*, <http://ctep.cancer.gov/resources/gcig/news032406.html>.

No fee is believed due for this submission. If any fees are required for the submission of this paper, or to avoid the abandonment of this application, please charge such fees to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date: September 10, 2007

  
\_\_\_\_\_  
Hoon Choi Ltd Reg. No. L0209  
For Anthony M. Insogna Reg No. 35,203  
**JONES DAY**  
12265 El Camino Real  
Suite 200  
San Diego, California 92130-4096